DUBLIN, April 6, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will join the Company as Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company’s engagement with the investment community, and will work with the Company’s Executive Leadership Team to develop and execute the Company’s long-term business strategy. Ms. Karydas will report to Tessa Hilado, Chief Financial Officer of Allergan.
“I am delighted to name Daphne to this new role and excited to work with her to continue to enhance our relationships with the investment community, while simultaneously focusing on our long-term growth strategy,” said Hilado. “Daphne’s outstanding reputation and strong relationships across the financial community coupled with her deep healthcare and industry knowledge provides an excellent fit for this newly created role. She will be a vital leader for our organization as Allergan continues to deliver short- and long-term growth for our shareholders.”
“Daphne brings to our team a tremendous mix of financial, healthcare and biopharma industry leadership. She also brings an outstanding perspective on industry and macroeconomic trends that provide the fire power necessary to identify and set strategic objectives that enhance our Growth Pharma leadership position,” said Brent Saunders, Chairman and Chief Executive Officer of Allergan. “I am excited to work with Daphne as we continue building the most dynamic Company in the biopharmaceutical industry.”
Ms. Karydas has more than 16 years of industry experience as a leading institutional investor and financial analyst in the biopharmaceutical sector, most recently at J.P. Morgan Asset Management. Previously, she was a healthcare Equity Research Analyst and Portfolio Manager at The Boston Company Asset Management, a Bank of New York Mellon company. Before joining The Boston Company, Ms. Karydas was a Vice President at Goldman Sachs where she worked in the Investment Banking Division as well as Goldman Sachs Asset Management focused on healthcare companies. Earlier in her career, she was a Project Chemical Engineer at Merck & Co. in the Vaccines division where she focused on process development for novel vaccines.
Ms. Karydas holds a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, surgical and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Allergan plc